Sphenopalatine Ganglion Block for Treatment of Postdural Puncture Headache in the Emergency Department: A Prospective, Randomized, Double-Blind Placebo Controlled Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Postdural Puncture Headache
- Sponsor
- University of Arkansas
- Locations
- 1
- Primary Endpoint
- Pain level with Verbal Rating Scale
- Status
- Withdrawn
- Last Updated
- 6 years ago
Overview
Brief Summary
This study evaluates sphenopalatine ganglion block (SPGB) for the treatment of postdural puncture headache (PDPH) in the emergency department (ED). Half of the patients will receive a true nerve block with lidocaine and bupivacaine. The other half will receive a placebo nerve block.
Detailed Description
Postdural puncture headaches (PDPH) are a common consequence of diagnostic lumbar puncture. The gold standard treatment for a PDPH is currently an autologous epidural blood patch (AEBP), which involves placing a needle into the epidural space of the spine and then injecting 20 ml of the patients own blood through the needle and into the epidural space to form a clot over the tear in the tissue layer that causes the headache. This is an invasive procedure that carries risks of pain, bleeding, infection, and in rare cases, neurological complications. We want to test the efficacy of using a less invasive procedure, called a sphenopalatine ganglion block (SPGB), for treatment of PDPH. SPGB has been used for many years in the treatment of migraines and cluster headaches, and there are several case reports of its use to successfully treat PDPH as well. SPGB simply involves applying a local anesthetic to the mucosa in the back of each nostril to numb the nerves that cause the headache. We hope that the SPGB will reduce the number of PDPH patients that require an AEBP.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Active postdural puncture headache within 7 days after diagnostic lumbar puncture
- •Age ≥ 18 years.
- •American Society of Anesthesiologists (ASA) physical status ≤ 3
Exclusion Criteria
- •Known coagulopathy
- •Known nasal septal deviation or abnormalities
- •Medical conditions contraindicated to lidocaine or bupivacaine
Outcomes
Primary Outcomes
Pain level with Verbal Rating Scale
Time Frame: 5 days
Patients will be asked to self rate their pain with 0 as no pain at all up to 10 being the worst pain imaginable.